Ann: Oncolytic Virotherapy CF33 Patent Granted in Japan, page-26

More good news

Interesting to note that Daiichi Sanyo gained approval last year to bring an oncolytic virus to market in Japan - the first such approval in Japan. The approval (conditional) was granted on the basis of one single arm ph 2 study with no control group.
https://pharmaphorum.com/news/daiichi-sankyo-claims-first-okay-for-cancer-killing-virus-in-japan/

I have previously suggested Daiichi as a possible partner for Imugene - with regard to Her-Vaxx. Daiichi is trying hard to expand their oncology portfolio. It’s a fair bet they would be interested in CF33 too.

Just a thought. Late night here for me though, so I’m off to bed. Wake me if anything else exciting happens….

Cheers

Dave